We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum S-100β Elevated in Septic Shock Patients with Delirium

By LabMedica International staff writers
Posted on 30 Aug 2018
Print article
Image: An S-100β (Human)-ELISA Kit (Photo courtesy of Yanaihara Institute).
Image: An S-100β (Human)-ELISA Kit (Photo courtesy of Yanaihara Institute).
A high prevalence of delirium is observed in sepsis, yet specific markers for this brain dysfunction in sedated patients are still lacking. Cytoplasmic low molecular weight calcium-binding protein, S-100β, is a commonly used nonspecific marker for brain injury.

S-100β is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S-100β. It has been shown that S-100β is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. Increases in S-100β levels have been evaluated whether there is an association in patients with delirium.

Scientists at the University of Oulu (Oulu, Finland) carried out an observational study included 22 patients with septic shock. Delirium was assessed by the Confusion Assessment Method (CAM) score for use in intensive care unit patients (CAM-ICU). Blood samples were obtained to measure inflammatory biomarkers: C-reactive protein (CRP), Procalcitonin (PCT), interleukin-6 (IL-6), IL-17, Tumor necrosis factor-alpha (TNF-α) and cerebral biomarkers such as S-100β, neuron-specific enolase (NSE), and two others. Patients were categorized according to the presence of delirium.

The scientists found that delirium was present in 10/22 of the patients (45.5%). Serum S-100β levels were above the laboratory cutoff value of 0.15 μg/L in 13/22 (59.1%) of the patients. The odds ratio for risk of developing delirium in cases with an S-100β greater than 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6 compared to those without; 138.3 pg/mL (range: 28.0-296.7) versus 53.6 pg/mL (range 109.3-505). There was a positive correlation between S100-β and IL-6 levels. Delirium patients had higher SOFA scores; 10 versus 7.

The authors concluded that delirium in septic shock was associated with an elevated protein S-100β when using a laboratory cutoff value of 0.15 μg/L and with more severe organ dysfunction during the ICU stay. The study was published on August 5, 2018, in the journal Acta Anaesthesiologica Scandinavica.

Related Links:
University of Oulu

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more